Fungal
Cryptococcus neoformans Infection Models
In vivo efficacy testing against Cryptococcus neoformans, the top-ranked WHO critical-priority fungus, in CNS and pulmonary models with fungal burden and survival endpoints.
Cryptococcus neoformans (C. neoformans) is an encapsulated environmental yeast and the leading cause of fungal meningitis. Its spores and desiccated yeast cells are inhaled from the environment by nearly everyone, usually without consequence; but in people with impaired cell-mediated immunity (most commonly advanced HIV/AIDS, but also transplant recipients and patients on corticosteroids) it establishes infection and disseminates. The usual entry point is the lung, where it causes pulmonary cryptococcosis, but the disease that defines its danger is neurologic: C. neoformans is neurotropic, which means it can cross into the central nervous system and cause cryptococcal meningoencephalitis, the second leading cause of death among people with HIV/AIDS worldwide. Skin, eyes, bone, joints, and myocardium can also be involved.
Its signature virulence factor is a thick polysaccharide capsule that blunts the host’s immune response, and its treatment is protracted and difficult. The WHO ranks C. neoformans at the very top of its 2022 Fungal Priority Pathogens List, making it the single highest-ranked fungal pathogen in the critical-priority group. TransPharm Preclinical Solutions evaluates candidates against C. neoformans in vivo in central-nervous-system and pulmonary infection models, producing the quantitative burden and survival data an antifungal program needs.
Scientific Scope
The scientific problem in a C. neoformans study is that the most severe disease it causes – meningoencephalitis – is the hardest to reach. Infection starts in the lung after inhalation, but survival depends on whether a candidate can reach and clear fungus that has crossed the blood-brain barrier into the central nervous system. TransPharm Preclinical Solutions’s models let a program address both compartments directly – a CNS challenge and a pulmonary challenge – rather than inferring CNS activity from systemic data.
Cryptococcosis is a disease of impaired immunity, so the immune state of the model shapes how disease progresses and how a candidate should be interpreted. Strain identity matters, too. The validated isolate, ATCC 24067, is a serotype D strain originally recovered from the cerebrospinal fluid of a patient with cryptococcal meningitis; because serotype A (var. grubii) accounts for the majority of clinical disease globally, serotype selection is worth confirming for a program aimed at the dominant clinical population. TransPharm Preclinical Solutions maintains an on-site library of hundreds of validated pathogens and can source or validate characterized C. neoformans isolates to a program’s specifications.
Validated Infection Models
Every study parameter is configurable to the scientific question: challenge strain, host species and strain, immune status, route of administration, comparator agents, and dosing schedule. The core readouts are quantitative fungal burden in target tissues, organs, and blood, with survival and mortality tracking where applicable.
The following are available as add-ons to any study:
- Pharmacokinetic profiling and PK/PD analysis
- Blood chemistry
- Additional tissue harvests
- Histopathology
Intracranial Infection
Cryptococcal meningoencephalitis is the disease that makes C. neoformans a critical-priority pathogen, and the intracranial model reproduces central-nervous-system infection directly. Animals are challenged by injection through the cisterna magna into the subarachnoid space – delivering the fungus to the cerebrospinal fluid compartment where clinical disease plays out – and can then be treated by a candidate given orally, intracranially, or by subcutaneous, intravenous, or intraperitoneal injection. This is the appropriate model when the development question is control of established CNS infection or penetration of an agent to the infected brain. Endpoints include survival and fungal burden in the brain and other harvested organs and/or blood. Validated in mice. Validated C. neoformans isolate: ATCC 24067.
Pulmonary Infection
The lung is the portal of entry for C. neoformans, and pulmonary cryptococcosis is the most common presentation. The pulmonary model is the appropriate choice when the question is reduction of fungal burden in the lung, survival after airway challenge, or delivery of an inhaled or systemically dosed agent to an infected lung. Animals are challenged by intranasal or intratracheal instillation. Test article may be delivered by nebulization, oral gavage, intranasal or intratracheal instillation, or by intravenous, intraperitoneal, intramuscular, or subcutaneous injection. Endpoints include survival and fungal burden in lung and other harvested tissues. Validated in mice. Validated C. neoformans isolate: ATCC 24067.
In Vitro Susceptibility Testing
In vitro antifungal susceptibility testing complements the in vivo models. For a yeast, the reference method is broth microdilution MIC (CLSI M27), which can be paired with time-kill and checkerboard analysis – the latter directly relevant here, since first-line cryptococcal therapy is itself a combination and a candidate is often assessed alongside it.
Antifungal Therapy and Resistance
C. neoformans is treated in stages, and each stage is a pressure point for new agents. Severe disease is managed by induction with amphotericin B plus flucytosine, followed by consolidation and long-term maintenance with fluconazole, which is a course that can run for months. The difficulty is less intrinsic pan-resistance than the combination of a protected CNS sanctuary, a limited set of antifungal classes, and the reduced fluconazole susceptibility (including heteroresistance) that emerges over prolonged maintenance and in relapse. Amphotericin B access and toxicity constrain use in the highest-burden settings, and flucytosine availability is limited in much of the world. Because the challenge strain’s susceptibility profile and the compartment being treated both shape what a study can demonstrate, strain choice and model choice – CNS versus lung – determine what an efficacy package can claim.